Splanchnic, Portal, Pelvic, and Miscellaneous Venous Disorders

57.1Start with venous territory and organ risk

Splanchnic and pelvic venous disorders are best organized from the threatened bed outward. Portal vein thrombosis threatens portal inflow, variceal bleeding control, transplant planning, and the ability to create or revise TIPS; mesenteric venous thrombosis threatens bowel viability; hepatic venous or caval outflow obstruction in Budd-Chiari syndrome threatens congestive liver failure and portal-hypertensive decompensation; pelvic venous reflux or obstruction usually threatens function and quality of life rather than immediate organ survival. That territorial map prevents the common error of treating every unusual-site venous diagnosis as the same disease. General unusual-site thrombosis guidance supports this anatomic framing, while portal-specific guidance separates cirrhotic, non-cirrhotic, malignant, and procedure-related contexts because each changes the risk-benefit balance of anticoagulation and intervention. EASL Clinical Practice 2026 · Vascular Liver Disorders 2020 · Guidance management venous 2016

Portal thrombosis in cirrhosis is not simply a clot in an inconvenient location. The surgeon has to ask whether thrombosis is recent or chronic, whether it is occlusive or progressive, whether it extends into the mesenteric venous system, whether varices are untreated, and whether future TIPS or transplant access is being compromised. AASLD and EASL guidance frame portal vein thrombosis within the broader management of vascular liver disease, and the AGA clinical update emphasises that cirrhotic PVT decisions should be coordinated with anticoagulation, endoscopic or pharmacologic variceal management, decompression strategy, and transplant planning rather than handled as an isolated anticoagulation question. EASL Clinical Practice 2026 · AGA Clinical Practice 2025 · Vascular Liver Disorders 2020

Acute mesenteric venous thrombosis is the diagnosis in this group where repeated bedside examination carries the greatest weight. In the absence of peritonitis or established infarction, immediate anticoagulation is the usual first treatment; however, the patient must be reassessed for worsening pain, sepsis, acidosis, peritoneal signs, or imaging progression because bowel necrosis changes the problem from venous thrombosis to threatened intestine. WSES acute mesenteric ischemia guidance is useful here only for this bowel-threat principle: venous thrombosis without peritonitis is managed differently from arterial occlusion, but the threshold for operative assessment rises quickly once infarction is suspected. WSES 2022 · Guidance management venous 2016

Budd-Chiari syndrome belongs in venous reconstruction practice because the treatable lesion is hepatic venous or caval outflow obstruction. The operative sequence is usually stepwise: anticoagulation and liver-directed medical care are paired with an anatomic assessment of hepatic veins and the IVC; short obstructive lesions may be candidates for recanalization, angioplasty, or stenting; and TIPS or DIPS is used when outflow cannot be restored directly or when decompression is required by severity. APASL, EASL, and the Seijo stepwise experience all support the principle that the first procedure should match the obstructed segment rather than default automatically to shunting. EASL Clinical Practice 2026 · Budd-Chiari syndrome consensus 2021 · Good long-term outcome 2013

Porto-sinusoidal vascular disease and other non-cirrhotic portal-hypertensive states remind the surgeon that preserved liver function does not equal low venous risk. These patients may have portal-hypertensive complications and may develop portal thrombosis despite the absence of conventional cirrhosis physiology. The practical point is not to assume benignity from preserved synthetic function: portal patency, variceal risk, and future decompression options still need deliberate review. EASL Clinical Practice 2026

57.2Describe portal and splanchnic thrombosis precisely

The first report to the treating team should not say only “PVT”. It should specify the involved segments—main portal vein, right or left branches, splenic vein, superior mesenteric vein, inferior mesenteric vein, hepatic veins, or IVC—then add acuity, occlusiveness, cavernous transformation, extension, cirrhotic or malignant context, inflammatory trigger, bowel findings, and current bleeding risk. AASLD, EASL, and unusual-site thrombosis guidance all make the same practical demand: management changes when thrombosis is recent rather than chronic, partial rather than occlusive, isolated rather than mesenteric, bland rather than malignant, and stable rather than progressive. EASL Clinical Practice 2026 · Vascular Liver Disorders 2020 · Guidance management venous 2016

For acute mesenteric venous thrombosis without peritonitis, anticoagulation is definitive first-line treatment, not a gesture while waiting for intervention. Heparin-based therapy is favoured early because the patient may need rapid adjustment around procedures, bleeding, or surgery; longer-term therapy is then tailored to whether the event was provoked by a transient factor or driven by persistent thrombophilia, malignancy, inflammatory disease, or idiopathic risk. A systematic review of splanchnic vein thrombosis found anticoagulation associated with improved thrombotic outcomes without treating bleeding risk as an automatic reason to withhold therapy, but the decision still has to be individualised when portal hypertension, varices, thrombocytopenia, or urgent surgery are present. Guidance management venous 2016 · Anticoagulant therapy splanchnic 2021

Direct oral anticoagulants have become part of the discussion for selected splanchnic venous thrombosis patients, but they should not be used as a reflex substitute for a territorial diagnosis. The 2023 systematic review and meta-analysis on DOACs in splanchnic vein thrombosis supports their consideration in selected patients, while leaving important exclusions for advanced liver disease, high-risk bleeding, drug interactions, renal dysfunction, antiphospholipid syndrome, and situations where reversibility or procedural control is central. In practice, the vascular team should decide first what venous bed is threatened and what procedures may be needed, then choose the anticoagulant with hepatology, haematology, and interventional colleagues. Vascular Liver Disorders 2020 · DOAC 2023

Endovascular escalation in mesenteric venous thrombosis is a selected rescue pathway after inadequate response to anticoagulation or evolving bowel threat, not a replacement for initial anticoagulation in stable patients. A small tertiary-center SMVT series supports the feasibility of thrombectomy, catheter-directed thrombolysis, and stenting in carefully selected patients, but its size and selection mean it should be used to justify expert-center discussion rather than broad routine intervention. WSES guidance should be kept to the relevant principle: persistent or worsening bowel threat changes management, and any endovascular plan must be integrated with the ability to operate if infarction declares itself. WSES 2022 · Superior Mesenteric Venous 2022

In cirrhosis, portal thrombosis decisions are inseparable from variceal bleeding prevention and future portal access. Anticoagulation may be chosen to prevent extension, promote recanalization, preserve transplant options, or maintain a feasible TIPS route; observation may be appropriate in selected chronic, minimally occlusive, or stable situations; and decompressive intervention is considered when portal-hypertensive complications or transplant strategy require it. AGA, AASLD, EASL, and the Shanghai consensus all support coordinated decision-making rather than a single rule that all cirrhotic PVT is either anticoagulated or ignored. EASL Clinical Practice 2026 · AGA Clinical Practice 2025 · Vascular Liver Disorders 2020 · Consensus management portal 2020

57.3Pelvic venous disease needs classification before treatment

Pelvic venous disease should not be reduced to a single syndrome with a single procedure. The SVP classification organises pelvic venous disorders by Symptoms, Varices, and Pathophysiology: the clinical syndrome is described by pelvic and extrapelvic symptoms, the venous reservoir is described separately, and the mechanism is identified as reflux, obstruction, mixed disease, or another etiology. This is more useful than older labels alone because “pelvic congestion”, “nutcracker”, and “May-Thurner” may describe anatomy without proving that the anatomy is causing the patient’s symptoms. SVP Classification Pelvic 2021

The immediate clinical value of SVP is that it forces symptom-anatomy-hemodynamic correlation before treatment. A dilated ovarian vein, parauterine varices, vulvar varices, lower-extremity varices of pelvic origin, renal vein compression, or iliac narrowing should not automatically trigger embolisation or stenting. The pelvic evaluation literature stresses that treatment should follow a coherent match among symptom distribution, variceal reservoir, reflux or obstruction, and exclusion of other pelvic, gynaecologic, gastrointestinal, urologic, musculoskeletal, or neuropathic causes. Diagnosis Management Pelvic 2024 · Clinical Presentation Evaluation 2021

For selected women with symptomatic pelvic venous reflux, embolotherapy can be a reasonable treatment once classification and correlation are complete. A 2024 systematic review of pelvic congestion embolotherapy reported high technical success and consistent improvement in chronic pelvic pain across included studies, with improvement also described for dyspareunia and dysmenorrhoea in the studies that reported those outcomes. These data support embolisation as a symptom-directed procedure in selected patients, not as a response to incidental dilated veins on cross-sectional imaging. Embolotherapy Pelvic Congestion 2024 · Diagnosis Management Pelvic 2024

Counseling should be explicit that pelvic venous embolotherapy data are mostly observational. Recurrence, reintervention, and minor complications occur, and response definitions vary across studies, so follow-up should track the patient’s presenting symptom complex rather than merely document coil position or ovarian-vein closure. The endpoint is improved function and pain burden, not technical occlusion alone. Embolotherapy Pelvic Congestion 2024

Pelvic venous obstruction belongs in the same framework as reflux. Iliac obstruction, renal vein compression, post-thrombotic pelvic outflow disease, and mixed reflux-obstruction phenotypes can all produce pelvic or extrapelvic symptoms, but stenting is justified only when symptoms and hemodynamic obstruction correlate. Contemporary pelvic venous disease guidance and the iliac-stenting literature support this restraint: stents should not be placed for anatomic narrowing alone, and embolisation-only treatment may underperform when the dominant problem is outflow obstruction. Diagnosis Management Pelvic 2024 · Role iliac vein 2024 · SVP Classification Pelvic 2021

57.4Clinical integration, follow-up, and evidence boundaries

The management sequence for splanchnic and pelvic venous disorders is territory, acuity, organ threat, and future access. In portal thrombosis, the team asks whether portal inflow must be preserved for TIPS or transplant and whether bleeding risk has been stabilised; in mesenteric venous thrombosis, the team asks whether the bowel is still viable; in Budd-Chiari syndrome, the team asks whether hepatic venous or caval outflow can be reconstructed; in pelvic venous disease, the team asks whether symptoms match reflux, obstruction, or mixed pathophysiology. This order keeps treatment from being driven by the first abnormal image. Vascular Liver Disorders 2020 · Guidance management venous 2016 · SVP Classification Pelvic 2021

Follow-up after splanchnic venous thrombosis should be built around the initial hazard. After acute MVT, the early hazard is progression to bowel infarction despite anticoagulation, so clinical reassessment and repeat imaging are used when symptoms fail to improve or worsen. Later, the central question becomes anticoagulation duration: transient provoking factors, persistent thrombophilia, malignancy, inflammatory disease, recurrent thrombosis, cirrhosis, and transplant candidacy all change the duration discussion. Systematic review evidence and unusual-site thrombosis guidance support anticoagulation as the core therapy while leaving room for individualised duration and drug choice. Guidance management venous 2016 · Anticoagulant therapy splanchnic 2021

Follow-up after Budd-Chiari intervention should assume that the first technical success may not be the last procedure. The stepwise Budd-Chiari literature supports recanalization of hepatic venous or caval obstruction when feasible and shunting when anatomy or severity requires it, but restenosis, shunt dysfunction, progressive liver disease, and portal-hypertensive complications require surveillance. The correct expectation is longitudinal venous and liver care, not a single definitive procedure detached from hepatology follow-up. Budd-Chiari syndrome consensus 2021 · Good long-term outcome 2013

Pelvic venous follow-up is different because the endpoint is symptom response and function. Closure of a refluxing reservoir, placement of an iliac stent, or improvement in venographic appearance is not enough if pelvic pain, dyspareunia, vulvar varices, or lower-extremity varices persist. Follow-up should therefore repeat the same clinical language used before treatment: symptom domain, variceal reservoir, pathophysiology, adjunctive gynaecologic or pain diagnoses, and need for staged treatment when reflux and obstruction coexist. Diagnosis Management Pelvic 2024 · Clinical Presentation Evaluation 2021

The evidence boundary should be stated plainly during consent and team planning. Portal and splanchnic anticoagulation recommendations rest on guidance documents and observational synthesis; SMVT endovascular rescue data are small and selected; Budd-Chiari reconstruction data are largely observational but reinforced by consistent stepwise practice; and pelvic venous embolisation or stenting studies vary in selection and symptom definitions. The honest message for trainees is that these interventions can be high-value in the right patient, but the indication must be anchored to anatomy, mechanism, clinical failure pattern, and center expertise. WSES 2022 · Superior Mesenteric Venous 2022 · Diagnosis Management Pelvic 2024